Selenium inhibits growth of trastuzumab-resistant human breast cancer cells via downregulation of Akt and beclin-1.
The response rate to treatment with trastuzumab (Tz), a recombinant humanized anti-HER2 monoclonal antibody, is only 12-34% despite demonstrated effectiveness on improving the survival of patients with HER2-positive breast cancers. Selenium has an antitumor effect against cancer cells and can play a...
Guardado en:
Autores principales: | Joohyun Woo, Jong Bin Kim, Taeeun Cho, Eun Hye Yoo, Byung-In Moon, Hyungju Kwon, Woosung Lim |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/78b47d50ead644189f86b73bdae4f555 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Impact of Multifocality on the Recurrence of Papillary Thyroid Carcinoma
por: Joohyun Woo, et al.
Publicado: (2021) -
The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric Cancers
por: Hye Ryeon Kim, et al.
Publicado: (2021) -
14-3-3Tau regulates Beclin 1 and is required for autophagy.
por: Bing Wang, et al.
Publicado: (2010) -
Antitumor Effects of Selenium
por: Seung Jo Kim, et al.
Publicado: (2021) -
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021)